凱普生物(300639.SZ)：擬通過控股子公司新設部分第三方醫學實驗室和司法鑑定所
格隆匯7月6日丨凱普生物(300639.SZ)公佈，公司為加快第三方醫學實驗室和司法鑑定所的建設，擬通過控股子公司廣州凱普醫學檢驗發展有限公司(“凱普醫學檢驗”)新設部分第三方醫學實驗室和司法鑑定所，並對現有部分第三方醫學實驗室進行升級建設，同時授權總經理管喬中先生根據市場情況變化決定新設醫學實驗室和司法鑑定所的具體選址、建設規模、診療科目/業務範圍等及擬升級建設的醫學實驗室的建設規模和方式及其最終實施，涉及需要提交公司董事會和股東大會審議的，將按規定履行審議程序並履行信息披露義務。
第三方醫學檢驗和司法鑑定業務規劃是公司在大健康產業的重大戰略佈局。近年來，受益於國家政策的良好推動和技術的進步，我國第三方醫學實驗室數量迅速增長，行業市場規模也在逐年擴大，但與美國、日本等發達國家相比，我國第三方醫學檢驗服務市場的滲透率較低，我國第三方醫學檢驗服務市場還有較大的發展潛力。2020年新冠疫情爆發後，醫療機構面對巨大的核酸檢測壓力，市場需求增加。國家政策的扶持以及廣闊的市場需求給第三方醫學檢測服務帶來了重大發展機遇。第三方醫學實驗室檢驗業務是公司近幾年的重點發展的方向，公司已打造形成“核酸檢測產品+醫學檢驗服務”的一體化經營模式，並初步建立起輻射全國的第三方醫學檢驗服務網絡。鑑於第三方醫學檢驗和司法鑑定行業發展迅速，未來前景較好，並存在巨大的市場空間，公司擴大醫學檢驗服務和司法鑑定服務的市場佈局，加快相關實驗室建設，並對現有部分第三方醫學實驗室升級建設，增加檢驗專業，豐富檢測種類，提升檢測能力，有利於進一步滿足當前市場複雜、多樣的檢測需求，並長遠支撐公司持續打造“核酸檢測產品+醫學檢驗服務”一體化經營模式，提升公司在第三方醫學檢驗服務行業的地位，擴大公司業務的市場佔有率，同時充分利用公司在第三方醫學檢驗業務積累的人才優勢、設備優勢和技術優勢，公司緊抓行業發展的機遇，加大司法鑑定業務的布局，推進基因科技助力司法公正，將促進公司司法鑑定業務的規模化發展，增強公司的可持續發展能力和核心競爭力，符合公司的發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
